Research translation follows diverse, often iterative pathways shaped by the type of innovation and context. Across all pathways, translation moves from discovery and development to evidence generation, real world implementation and scale up, with the shared goal of delivering benefits for patients, communities and health systems.

The NHMRC Research Translation Strategy 2026–2030 highlights 5 common research translation pathways to impact. NHMRC will continue to add case studies for each of the pathways below to demonstrate real-world examples showcasing the stages, timelines and stakeholders involved in both commercial and non-commercial pathways.

Case studies

Therapeutic products

(For example, drugs, biologics and advanced therapies)

Medical devices, diagnostics and biomarkers

  • Case study under development 

Digital health

(Including AI‑enabled technologies and connected health solutions)

Clinician-delivered and procedural interventions

(For example, therapies, rehabilitation, surgical and lifestyle interventions)

  • Case study under development

Public health and health system-level interventions

(For example, prevention, policy, service redesign and system improvement)

Across these pathways, impact may be achieved through both non-commercial and commercial approaches, supported by strong collaboration and evidence generation, including clinical trials and real-world studies.